{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:13:35Z","timestamp":1792199615722,"version":"4.4.0"},"reference-count":16,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003516","name":"EveryCat Health Foundation","doi-asserted-by":"publisher","award":["EC24F-297"],"award-info":[{"award-number":["EC24F-297"]}],"id":[{"id":"10.13039\/100003516","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Antiviral drugs like EIDD-2801 (molnupiravir; MPV) have been successfully used in the treatment of feline infectious peritonitis (FIP). The previous study of the pharmacokinetics of MPV in healthy cats showed promise for its use and safety. The objective was to determine the pharmacokinetics of molnupiravir in cats with naturally occurring FIP by measuring MPV and EIDD-193 (\u03b2-D-N4-hydroxycytidine; NHC) serum levels. Blood was collected from seven cats diagnosed with naturally occurring FIP treated at 1, 2, 4, 6 and 12 h post oral MPV administration and at 12 h post pill administration 7 days later. Serum concentrations of MPV and NHC were determined using a previously published high-performance liquid chromatography\u2013tandem mass spectrometry (HPLC-MS\/MS) method. The mean dose of MPV was 15.44 mg\/kg (SD \u00b1 1.82). The mean peak serum concentration of MPV (Cmax) after a single PO dose of MPV was 38 ng\/mL (SD \u00b1 5). The mean peak serum concentration of NHC (Cmax) after a single PO dose of MVP was 1551 ng\/mL (SD \u00b1 720). the time to reach NHC Cmax (Tmax) was 2.6 h (SD \u00b1 1.4), and the NHC elimination half-life was 1.6 h (SD \u00b1 1.1). Minimal drug accumulation was seen in trough concentrations following twice-daily dosing for 7 days. The low MPV levels may be explained by fast conversion to its active metabolite NHC. The mean NHC concentrations at all time points were at least 4 times the reported in vitro IC50 for feline coronavirus strains and twice-daily dosing for seven days did not lead to drug accumulation within the serum. The results support the use of MPV in the treatment of FIP, and if therapeutic drug monitoring is to be performed, NHC should be measured.<\/jats:p>","DOI":"10.3390\/pathogens14070666","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:58:23Z","timestamp":1751878703000},"page":"666","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics of Molnupiravir in Cats with Naturally Occurring Feline Infectious Peritonitis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-8534","authenticated-orcid":false,"given":"Petra","family":"\u010cern\u00e1","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Wittenburg","sequence":"additional","affiliation":[{"name":"Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hawley","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenna","family":"Willis","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegenthaler","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Lappin","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jfms.2008.09.008","article-title":"A review of feline infectious peritonitis virus infection: 1963\u20132008","volume":"11","author":"Pedersen","year":"2009","journal-title":"J. Feline Med. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14122","DOI":"10.1128\/JVI.79.22.14122-14130.2005","article-title":"Acquisition of macrophage tropism during the pathogenesis of feline infectious peritonitis is determined by mutations in the feline coronavirus spike protein","volume":"79","author":"Rottier","year":"2005","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vetmic.2018.04.026","article-title":"The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies","volume":"219","author":"Murphy","year":"2018","journal-title":"Vet. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1098612X19825701","article-title":"Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis","volume":"21","author":"Pedersen","year":"2019","journal-title":"J. Feline Med. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1098612X231194460","DOI":"10.1177\/1098612X231194460","article-title":"Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020\u20132022)","volume":"25","author":"Taylor","year":"2023","journal-title":"J. Feline Med. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cook, S., Wittenburg, L., Yan, V.C., Theil, J.H., Castillo, D., Reagan, K.L., Williams, S., Pham, C.-D., Li, C., and Muller, F.L. (2022). An optimized bioassay for screening combined anticoronaviral compounds for efficacy against feline infectious peritonitis virus with pharmacokinetic analyses of GS-441524, remdesivir, and molnupiravir in cats. Viruses, 14.","DOI":"10.3390\/v14112429"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/jvim.16832","article-title":"Molnupiravir treatment of 18 cats with feline infectious peritonitis: A case series","volume":"37","author":"Sase","year":"2023","journal-title":"J. Vet. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Roy, M., Jacque, N., Novicoff, W., Li, E., Negash, R., and Evans, S.J. (2022). Unlicensed molnupiravir is an effective rescue treatment following failure of unlicensed GS-441524-like therapy for cats with suspected feline infectious peritonitis. Pathogens, 11.","DOI":"10.3390\/pathogens11101209"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/jvim.17187","article-title":"Open label clinical trial of orally administered molnupiravir as a first-line treatment for naturally occurring effusive feline infectious peritonitis","volume":"38","author":"Reagan","year":"2024","journal-title":"J. Vet. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Amara, A., Penchala, S.D., Else, L., Hale, C., FitzGerald, R., Walker, L., Lyons, R., Fletcher, T., and Khoo, S. (2021). The development and validation of a novel LC-MS\/MS method for the simultaneous quantification of Molnupiravir and its metabolite \u00df-d-N4-hydroxycytidine in human plasma and saliva. J. Pharm. Biomed. Anal., 206.","DOI":"10.1016\/j.jpba.2021.114356"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13732","DOI":"10.1111\/cts.13732","article-title":"Molnupiravir: Mechanism of action, clinical, and translational science","volume":"17","author":"Maas","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e02428-20","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/cbdv.200900233","article-title":"The Biochemistry of Drug Metabolism\u2013An Introduction: Part 7. Intra-Individual Factors Affecting Drug Metabolism","volume":"6","author":"Kraemer","year":"2009","journal-title":"Chem. Biodivers."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/cts.13602","article-title":"Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants","volume":"16","author":"Iwamoto","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/avj.13433","article-title":"Treatment of feline infectious peritonitis in cats with molnupiravir: Clinical observations and outcomes for 54 cases","volume":"103","author":"Clark","year":"2025","journal-title":"Aust. Vet. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jsap.13849","article-title":"Pharmacokinetics of GS-441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021\u20132024)","volume":"66","author":"Coggins","year":"2025","journal-title":"J. Small Anim. Pract."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/7\/666\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:05:38Z","timestamp":1760033138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/7\/666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["pathogens14070666"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14070666","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}